In order to determine whether these checkpoint molecules can be used to differentiate among the IgG4-RD phenotypes, we examined the associations between the serum levels of Gal-9 or sTIM-3 and organ involvements in IgG4-RD patients. The gene discussed is LGALS9; the disease is immunoglobulin G4-related sclerosing disease.